TG Therapeutics
TGTX
45 hedge funds and large institutions have $27.7M invested in TG Therapeutics in 2013 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 11 reducing their positions, and 13 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 11
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
2% less funds holding
Funds holding: 46 → 45 (-1)
18% less capital invested
Capital invested by funds: $33.6M → $27.7M (-$5.88M)
30% less call options, than puts
Call options by funds: $64K | Put options by funds: $91K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$6.46M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.4M |
| 3 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$794K |
| 4 |
CCI
Columbus Circle Investors
|
+$654K |
| 5 |
BM
Bridger Management
New York
|
+$594K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$4.38M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.02M |
| 3 |
Millennium Management
New York
|
-$856K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$846K |
| 5 |
Neuberger Berman Group
New York
|
-$636K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARTA
51
A.R.T. Advisors
New York
| – | -$71K | -14,268 | Closed |
|
|
BRWA
52
B. Riley Wealth Advisors
Boca Raton,
Florida
| – | -$56K | -11,194 | Closed |
|
|
RFC
53
Russell Frank Company
Seattle,
Washington
| – | -$42K | -7,025 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$15K | -3,037 | Closed |
|
55
Ameriprise
Minneapolis,
Minnesota
| – | -$5K | -967 | Closed |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2K | -320 | Closed |
|
57
Bessemer Group
Woodbridge,
New Jersey
| – | +$8 | +2 | New |
|
TGTX Hedge Fund Activity: Q4 2013 in Review
45 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2013, worth a combined $27.7M — down 18% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of TGTX and 12 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 14 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $6.46M. The largest seller was Jennison Associates, cutting an estimated $4.38M.
- 45 institutional investors held TG Therapeutics (TGTX) as of Q4 2013, down from 46 in Q3 2013.
- Funds reported $27.7M of TG Therapeutics stock for Q4 2013, down 18% quarter-over-quarter.
- 12 funds opened new TG Therapeutics positions in Q4 2013 and 13 closed out, a net change of -1 holder.
- The largest TG Therapeutics buyer in Q4 2013 was Baker Bros. Advisors, an estimated $6.46M added.
- The largest TG Therapeutics seller in Q4 2013 was Jennison Associates, an estimated $4.38M sold.
Based on aggregated 13F filings for Q4 2013.